BAP Officer Details

Secretary for Clinical External Affairs

Professor Jeremy Hall

Jeremy Hall

University of Cardiff
Secretary for Clinical External Affairs until 2019

I took my first degree in biology at Oxford University before moving to Edinburgh to study preclinical medicine. I then completed my medical degree at Cambridge University as part of the MB/PhD programme. I studied for my PhD on the molecular correlates of emotional learning and memory under the supervision of Professor Barry Everitt in Cambridge. I then moved to Edinburgh where I have worked primarily on schizophrenia and related neurodevelopmental disorders. My clinical research has been supported by a Training Fellowship from the MRC and a senior Fellowship from the AMS/SFC as well as research grants from the Wellcome Trust, MRC and European Union and industrial collaborations (TMRI, Pfizer, Abbott). My current position is as Professor of Psychiatry and Neuroscience at Cardiff University and Director of the Cardiff Neuroscience and Mental Health Research Institute.

I believe that we are entering an unprecedented era of opportunity for the advancement of the understanding and treatment of major mental disorders such as schizophrenia, autism and bipolar disease. This opportunity derives, in particular, from advances in genetics and from the consequent availability of more refined model systems and translational tools. However, this opportunity is faces the major challenges of increased regulation, restrictions on research and a reluctance of pharmaceutical companies to continue to invest in research in this area.

The BAP is ideally placed to play a key role in bridging this gap between scientific opportunity and industry investment. Within the context of the BAP I would be keen to highlight the opportunities available for drug testing and development provided by iPS cell technology, transgenic models and imaging technologies. I will also be keen to develop opportunities for collaborative work across these platforms both between academic centres and between industry and academia and to publicise the positive benefits of active biological and pharmacological research in this area.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. No
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Abbvie, Pfizer, Astra Zeneca
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. No
  21. If there is anything else you feel it necessary to disclose, please provide details.

Form completed on 17th August 2017